Macrolides, fluoroquinolones reduce risk for anti-drug antibodies in IBD treatment

Macrolides, fluoroquinolones reduce risk for anti-drug antibodies in IBD treatment

Avoidance of cephalosporins and penicillin with beta-lactamase inhibitors during anti-TNF therapy reduced the risk for anti-drug antibodies among patients with inflammatory bowel disease, according to research published in Gut.“Primary non-response to anti-TNF therapy is seen in 40% of patients with even higher rates of failure to achieve complete remission. Additionally, the rate of secondary loss of response after 12 months of therapy ranges between 23% and 46%,” Yuri Gorelik, Rambam Health Care Campus in Haifa, Israel, and colleagues wrote. “Immunogenicity, which refersRead More

Share on facebook
Share on twitter
Share on linkedin